Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
Alpha Tau Medical Ltd. announced that its study evaluating the combination of Alpha DaRT, a novel alpha-radiation cancer therapy, with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC) has been selected for a podium presentation at the prestigious AHNS 12th International Conference …